Valneva vaccine approved for UK use is Covid jab which may be more effective for longer


A Covid-19 vaccine developed by Valneva has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency, with the British Medical Journal claiming the vaccine could appeal to those who are more hesitant about taking current vaccines on offer

Last year, Valneva said its latest trial, on 4,012 participants aged 18 and older across 26 trial sites in Britain, showed the vaccine prompted a stronger immune response

A new Covid jab which may be more effective for longer has been given approval.

A Covid-19 vaccine developed by Valneva has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency.

According to the British Medical Journal, the vaccine could appeal to those who are more hesitant about taking current vaccines on offer as they use relatively new technology in their rollout.

However, the Valneva vaccine uses more ‘conventional’ technology, according to the BMJ.

The BMJ states: “As a whole virus vaccine, it may be more effective over a longer period of time (as more variants emerge) than those vaccines only targeting SARS-CoV-2’s characteristics protein spikes.”

Last year, Valneva said its latest trial, on 4,012 participants aged 18 and older across 26 trial sites in Britain, showed the vaccine prompted a stronger immune response and fewer side-effects than AstraZeneca’s shot.







According to the British Medical Journal, the vaccine could appeal to those who are more hesitant about taking current vaccines
(

Image:

GettyImages)

In new phase three results reported on Monday, the Valneva vaccine showed around 40% higher neutralizing antibody titer levels compared with the vaccine from AstraZeneca in a head-to-head trial.

The company also said its vaccine – VLA2001 – induced broad T-cell responses, apart from the immune system believed to be involved in long-term immunity.

Adam Finn, professor of pediatrics at the University of Bristol and trial chief investigator, told a briefing that the figure for the vaccine’s efficacy would come when the jab is used in the population.

He said the Valneva jab is expected to be “at least as effective as, and potentially more effective than” the Oxford-AstraZeneca jab.

But he said “the efficacy of a vaccine is not proportional to the antibody titers that it generates”, and there tended to be a threshold above which people were protected against infection or serious illness.

“Enough antibody is what you need and more antibody may not be any better,” he added.







The company also said its vaccine – VLA2001 – induced broad T-cell responses, a part of the immune system believed to be involved in long-term immunity
(

Image:

AFP via Getty Images)

The phase three trial recruited 4,012 people across 26 trial sites in the UK, including around 3,000 who took part in the comparison with AstraZeneca.

The number of Covid-19 cases was similar between those given AstraZeneca and those given Valneva, the firm said.

It added that the complete absence of any severe Covid-19 cases may suggest that both vaccines used in the study prevented severe symptoms caused by circulating variants, mainly the Delta variant.

Prof Finn said: “The low levels of reactogenicity and high functional antibody responses alongside broad T-cell responses seen with this adjuvant inactivated whole-virus vaccine are both impressive and extremely encouraging.

“This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America, and these results suggest this vaccine candidate is on track to play an important role in overcoming the pandemic.”

Read More

Read More




www.mirror.co.uk

Related Posts

George Holan

George Holan is chief editor at Plainsmen Post and has articles published in many notable publications in the last decade.

Leave a Reply

Your email address will not be published. Required fields are marked *